Serum CDC42 level change during abiraterone plus prednisone treatment and its association with prognosis in metastatic castration-resistant prostate cancer patients

Serum CDC42 level change during abiraterone plus prednisone treatment and its association with prognosis in metastatic castration-resistant prostate cancer patients

Abstract Objective Cell division cycle 42 (CDC42) regulates prostate cancer growth and metastasis. This study aimed to evaluate the change in serum CDC42 during treatment and its association with the clinical features and prognosis in abiraterone plus prednisone treated metastatic castration-resista...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yong Ma, Zhihua Cao, Jiacheng Zhang, Xu Zhu, Zhonghao Zhao, Jinguo Xiong
Format:	Article
Language:	English
Published:	Springer 2025-03-01
Series:	Discover Oncology
Subjects:	Cell division cycle 42 Metastatic castration-resistant prostate cancer Abiraterone plus prednisone Clinical characteristics Prognosis
Online Access:	https://doi.org/10.1007/s12672-025-02130-0
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The Neutrophil-to-Lymphocyte Ratio as a Biomarker in Metastatic Castrate-Sensitive Prostate Cancer Patients Treated with Abiraterone Acetate
by: Caio Vinícius Suartz, et al.
Published: (2024-08-01)

Oral mucositis with abiraterone acetate: A therapeutic dilemma
by: Shaunak Valame, et al.
Published: (2020-01-01)

Meta-analysis to evaluate the comparative effectiveness of enzalutamide and abiraterone acetate for first-line treatment of metastatic castration-resistant prostate cancer in real-world settings
by: Armen Aprikian, et al.
Published: (2025-02-01)

Prognostic factors for patients treated with abiraterone
by: Cecília M Alvim, et al.
Published: (2020-02-01)

A Super‐Enhancer‐Driven Transcriptional Regulatory Circuit Underlying Abiraterone Resistance in Castration‐Resistant Prostate Cancer
by: Liling Jiang, et al.
Published: (2025-08-01)

Short-term efficacy of enzalutamide in treatment of patients with abiraterone-resistant metastatic castration-resistant prostate cancer
by: MEI Jingchang, SU Xiaonan, YAO Yu, GUAN Fengju, ZHANG Guiming
Published: (2025-02-01)

A randomized, open-label, multi-center, active-controlled phase II study comparing abiraterone acetate tablets (II), an improved formulation, versus originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer
by: Xiaolin Lu, et al.
Published: (2025-05-01)

Efficacy and safety of darolutamide versus abiraterone acetate plus prednisone in combination with ADT for mHSPC: a real-world clinical retrospective study
by: Ting Hu, et al.
Published: (2025-06-01)

Prognostic value of prostate-specific antigen in advanced prostate cancer treated with androgen deprivation therapy and abiraterone
by: L. Lou, et al.
Published: (2024-11-01)

Pathologic response as an early endpoint for survival following neoadjuvant androgen deprivation therapy plus abiraterone acetate for metastatic prostate cancer
by: Kaichen Zhou, et al.
Published: (2025-04-01)

SURVIVAL EFFECT OF PALLIATIVE RADIOTHERAPY IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER DEVELOPING OLIGO-PROGRESSION UNDER ANTIANDROGEN TREATMENT
by: Sabin Göktaş Aydın, et al.
Published: (2023-03-01)

Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients
by: N. K. Mazina, et al.
Published: (2017-11-01)

Case Report: Abiraterone in brain metastases from prostate cancer
by: Tobias Peres, et al.
Published: (2025-04-01)

Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer
by: N. A. Avxentyev, et al.
Published: (2019-01-01)

Physician and Patient Preferences for the Treatment of Metastatic Castration-Sensitive and Castration-Resistant Prostate Cancer: A Best-Worst Scaling Study in Japan
by: Takahiro Kimura, et al.
Published: (2025-02-01)

Carbamazepine Rash and Prednisone
by: J Gordon Millichap
Published: (1991-02-01)

Comparison of PSA Response to Generic Versus Innovator (Zytiga) Formulations of Abiraterone in Metastatic CRPC: A Retrospective Analysis
by: Sharath Kumar, et al.
Published: (2025-08-01)

Utility of pembrolizumab for metastatic castrate resistant prostate cancer with MMR deficiency
by: Brian F. Dinerman, et al.
Published: (2024-11-01)

Clinical observations of patients with metastatic castration-resistant prostate cancer living in the Tambov region
by: P. G. Berezin, et al.
Published: (2023-09-01)

Adverse prognosis gene expression patterns in metastatic castration‐resistant prostate cancer
by: Marina N. Sharifi, et al.
Published: (2025-08-01)

Prescription pattern of abiraterone in Brazil - a survey of medical oncologists
by: João Pedro Homse-Netto, et al.
Published: (2023-08-01)

Study on the anaerobic biotreatment of prednisone wastewater
by: TU Zhan, et al.
Published: (2007-03-01)

Assessing the clinical outcomes of immunotherapy and docetaxel combinations in metastatic castration-resistant prostate cancer: a meta-analysis
by: Azka Syed, et al.
Published: (2025-07-01)

Efficacy Evaluation of Aspirin Plus Prednisone or Prednisolone in IVF/RIF Patients: A Systematic Review and Meta-Analysis
by: Yanyan Tang, et al.
Published: (2024-08-01)

Synergistic anticancer effect of CDRI-08 and Abiraterone acetate against castration resistant prostate cancer targeting PI3K/Akt pathway
by: Bhavana Jonnalagadda, et al.
Published: (2025-09-01)

Effect of prednisone on Th17/Treg immune balance in adult patients with primary nephritic syndrome
by: YANG Guo-sheng, et al.
Published: (2016-01-01)

Abiraterone and Galeterone, Powerful Tools Against Prostate Cancer: Present and Perspective
by: Ivana Z. Kuzminac, et al.
Published: (2024-10-01)

Intravenous methylprednisolone versus oral prednisone for initial attacks of optic neuritis, A review of evidence
by: Teresita R. Castillo, MD, MHPEd
Published: (2005-06-01)

Incidence and Risk of Thromboembolic and Cardiovascular Adverse Events with PARP Inhibitor Treatment in Patients with Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Safety Meta-analysis
by: Brigida Anna Maiorano, et al.
Published: (2025-02-01)

Effects of High-Dose Prednisone on the Gastrointestinal Microbiota of Healthy Dogs
by: Sarah Garrity, et al.
Published: (2025-03-01)

Therapy results of patients with metastatic castration‑resistant prostate cancer. Regional experience
by: P. G. Berezin, et al.
Published: (2023-03-01)

Prognostic Nutritional Index and a Blood-Based Prognostic Tool in Prostate Cancer Treated with Abiraterone, Enzalutamide or Cabazitaxel
by: Hakan Taban, et al.
Published: (2025-06-01)

Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer
by: Himisha Beltran, et al.
Published: (2025-08-01)

A Single-Center, Retrospective, Real-World, Observational Clinical Study to Evaluate the Safety and Efficacy of Abiraterone (Abiratred) in Patients with Metastatic Prostate Cancer
by: Pongwut Danchaivijitr, et al.

Effect of leflunomide combined with small-dose prednisone on the clinical efficacy of IgA nephropathy, renal functions and urine proteins
by: YANG Yan-ping, et al.
Published: (2019-01-01)

Dysphasia: metastatic prostate cancer to the leptomeninges: a case report
by: Diana Jodeh, et al.
Published: (2024-10-01)

Mutation in CDC42 Gene Set as a Response Biomarker for Immune Checkpoint Inhibitor Therapy
by: Kun Wang, et al.
Published: (2025-01-01)

A novel RP-HPLC stability-indicating method for simultaneous estimation of Niraparib and Abiraterone in synthetic mixtures and combined tablet formulations
by: Krishnaphanisri Ponnekanti, et al.
Published: (2025-05-01)

Effects of cdc42 gene knockout by CRISPR/Cas9 technology on osteochondral development in zebrafish
by: YANG Yunfei, et al.
Published: (2024-11-01)

Report of two narcoleptic patients with remission of hypersomnolence following use of prednisone Relato de dois casos de pacientes com narcolepsia com melhora dos sintomas após uso de prednisona
by: Fernando Morgadinho Santos Coelho, et al.
Published: (2007-06-01)